Last reviewed · How we verify
Niaspan
At a glance
| Generic name | Niaspan |
|---|---|
| Also known as | Extended release niacin, NIASPAN™, Extended-release nicotinic acid, Extended-release niacin, niacin |
| Sponsor | Cedars-Sinai Medical Center |
| Target | Hydroxycarboxylic acid receptor 3, Nicotinate-nucleotide pyrophosphorylase [carboxylating], Nicotinamide N-methyltransferase |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Familial hypercholesterolemia - heterozygous
- Hypercholesterolemia
- Hyperlipidemia
- Hypertriglyceridemia
- Mixed hyperlipidemia
- Vitamin deficiency
Common side effects
- Flushing
- Diarrhea
- Nausea
- Vomiting
- Increased cough
- Pruritus
- Rash
- Dizziness
- Tachycardia
- Palpitations
- Shortness of breath
- Sweating
Serious adverse events
- Syncope
- Rhabdomyolysis
- Diabetes mellitus
Key clinical trials
- Pilot Trial of Supplemental Vitamin A and Nicotinamide (EARLY_PHASE1)
- Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) (EARLY_PHASE1)
- Nicotinic Acid for the Treatment of Alzheimer's Disease (PHASE1, PHASE2)
- Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy (PHASE2)
- Supplementation With Sirtuin Activators in Women With Increased Body Weight (NA)
- Brown Adipose Tissue Metabolism in Type 2 Diabetes (NA)
- Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery (NA)
- Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Niaspan CI brief — competitive landscape report
- Niaspan updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI